Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

To the Editor: The SAME study affirmed the safety and efficacy of switching between originator and biosimilars and the potential for cost savings.¹ Yet the global uptake of biosimilars has been relatively slow² due to a number of factors, including marketing suggesting that such drugs are less safe or efficacious than the originator.³ Implicated in such marketing is confusion arising from the use of
the word “interchangeable”, which is a defined term under United States legislation. The word “substitution” is used in Australia, which raises the likelihood of further confusion.